{"id":62911,"date":"2026-04-12T11:50:14","date_gmt":"2026-04-12T03:50:14","guid":{"rendered":"https:\/\/flcube.com\/?p=62911"},"modified":"2026-04-12T11:50:15","modified_gmt":"2026-04-12T03:50:15","slug":"peijia-medical-doses-first-patient-in-us-early-feasibility-study-for-geminione-teer-system-expands-global-mitral-regurgitation-pipeline","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62911","title":{"rendered":"Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System \u2013 Expands Global Mitral Regurgitation Pipeline"},"content":{"rendered":"\n<p><strong>Peijia Medical Ltd<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/9996:HKG\">HKG:\u202f9996<\/a>) announced completion of the <strong>first patient implant<\/strong> in the <strong>Early Feasibility Study (EFS)<\/strong> for its <strong>GeminiOne transcatheter edge\u2011to\u2011edge repair (TEER) system<\/strong> in the <strong>United States<\/strong>. The milestone marks Peijia&#8217;s entry into the US structural heart market with its next\u2011generation mitral valve repair technology.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-milestone\">Clinical Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Study Type<\/strong><\/td><td>Early Feasibility Study (EFS)<\/td><\/tr><tr><td><strong>Location<\/strong><\/td><td>United States<\/td><\/tr><tr><td><strong>First Patient<\/strong><\/td><td>Implanted April\u202f2026<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>GeminiOne TEER system<\/td><\/tr><tr><td><strong>Target Indication<\/strong><\/td><td>Mitral regurgitation (MR)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-device-innovation-amp-differentiation\">Device Innovation &amp; Differentiation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Design Feature:<\/strong> <strong>Unique structural design<\/strong> enabling <strong>smaller implant size and delivery profile<\/strong><\/li>\n\n\n\n<li><strong>Clinical Advantage:<\/strong> Reduced procedural complexity vs. incumbent TEER systems; potential for <strong>broader physician adoption<\/strong> and <strong>expanded patient eligibility<\/strong><\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Global patent applications filed for system design<\/li>\n\n\n\n<li><strong>Competitive Position:<\/strong> Addresses size limitations of first\u2011generation TEER devices (e.g., Abbott MitraClip, Edwards Pascal)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-regulatory-progress\">Global Regulatory Progress<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Region<\/th><th>Status<\/th><th>Milestone Date<\/th><\/tr><\/thead><tbody><tr><td><strong>European Union<\/strong><\/td><td><strong>CE Mark certified<\/strong><\/td><td>Feb\u202f2026<\/td><\/tr><tr><td><strong>China<\/strong><\/td><td>NMPA review ongoing<\/td><td>Registration accepted; under review<\/td><\/tr><tr><td><strong>United States<\/strong><\/td><td>EFS initiated<\/td><td>Apr\u202f2026 (first patient)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-outlook\">Market Context &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mitral Regurgitation Market:<\/strong> Global <strong>US$5\u20117\u202fbillion<\/strong> annually; TEER segment growing <strong>15\u201120% CAGR<\/strong> as alternative to surgical repair<\/li>\n\n\n\n<li><strong>US Opportunity:<\/strong> Largest single market (~40% of global TEER volume); EFS completion enables <strong>pivotal trial initiation<\/strong> and <strong>premarket approval (PMA) pathway<\/strong><\/li>\n\n\n\n<li><strong>CE Mark Leverage:<\/strong> EU commercial launch expected <strong>H2\u202f2026<\/strong>, generating clinical data and revenue to support US regulatory submission<\/li>\n\n\n\n<li><strong>China Synergy:<\/strong> NMPA approval anticipated <strong>2027<\/strong>; domestic manufacturing cost advantages position for <strong>price\u2011competitive market entry<\/strong> vs. Abbott\/Edwards<\/li>\n\n\n\n<li><strong>Revenue Trajectory:<\/strong> Peak global sales potential estimated at <strong>US$300\u2011500\u202fmillion<\/strong> by 2032, assuming 8\u201112% TEER market share across US, EU, and China<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical trial progression, regulatory approvals, and commercial projections for GeminiOne. Actual results may differ due to risks including EFS outcomes, FDA regulatory requirements, competitive response from established TEER players, and reimbursement negotiations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040901753_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026040901753_c.\"><\/object><a id=\"wp-block-file--media-87792685-5f4e-4f99-91ce-54854d481d8a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040901753_c.pdf\">2026040901753_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/2026040901753_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-87792685-5f4e-4f99-91ce-54854d481d8a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Peijia Medical Ltd (HKG:\u202f9996) announced completion of the first patient implant in the Early Feasibility&#8230;<\/p>\n","protected":false},"author":1,"featured_media":62913,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,22],"tags":[62,69,1161,319],"class_list":["post-62911","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-medical-device","tag-clinical-trial-approval-initiation","tag-cvd","tag-hkg-9996","tag-peijia-medical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System \u2013 Expands Global Mitral Regurgitation Pipeline - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Peijia Medical Ltd (HKG:\u202f9996) announced completion of the first patient implant in the Early Feasibility Study (EFS) for its GeminiOne transcatheter edge\u2011to\u2011edge repair (TEER) system in the United States. The milestone marks Peijia&#039;s entry into the US structural heart market with its next\u2011generation mitral valve repair technology.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62911\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System \u2013 Expands Global Mitral Regurgitation Pipeline\" \/>\n<meta property=\"og:description\" content=\"Peijia Medical Ltd (HKG:\u202f9996) announced completion of the first patient implant in the Early Feasibility Study (EFS) for its GeminiOne transcatheter edge\u2011to\u2011edge repair (TEER) system in the United States. The milestone marks Peijia&#039;s entry into the US structural heart market with its next\u2011generation mitral valve repair technology.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62911\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-12T03:50:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-12T03:50:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1203.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62911#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62911\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System \u2013 Expands Global Mitral Regurgitation Pipeline\",\"datePublished\":\"2026-04-12T03:50:14+00:00\",\"dateModified\":\"2026-04-12T03:50:15+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62911\"},\"wordCount\":327,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62911#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1203.webp\",\"keywords\":[\"Clinical trial approval \\\/ initiation\",\"CVD\",\"HKG: 9996\",\"Peijia Medical\"],\"articleSection\":[\"Company\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62911#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62911\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62911\",\"name\":\"Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System \u2013 Expands Global Mitral Regurgitation Pipeline - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62911#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62911#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1203.webp\",\"datePublished\":\"2026-04-12T03:50:14+00:00\",\"dateModified\":\"2026-04-12T03:50:15+00:00\",\"description\":\"Peijia Medical Ltd (HKG:\u202f9996) announced completion of the first patient implant in the Early Feasibility Study (EFS) for its GeminiOne transcatheter edge\u2011to\u2011edge repair (TEER) system in the United States. The milestone marks Peijia's entry into the US structural heart market with its next\u2011generation mitral valve repair technology.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62911#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62911\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62911#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1203.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/04\\\/1203.webp\",\"width\":1080,\"height\":608,\"caption\":\"Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System \u2013 Expands Global Mitral Regurgitation Pipeline\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62911#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System \u2013 Expands Global Mitral Regurgitation Pipeline\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System \u2013 Expands Global Mitral Regurgitation Pipeline - Insight, China&#039;s Pharmaceutical Industry","description":"Peijia Medical Ltd (HKG:\u202f9996) announced completion of the first patient implant in the Early Feasibility Study (EFS) for its GeminiOne transcatheter edge\u2011to\u2011edge repair (TEER) system in the United States. The milestone marks Peijia's entry into the US structural heart market with its next\u2011generation mitral valve repair technology.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62911","og_locale":"en_US","og_type":"article","og_title":"Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System \u2013 Expands Global Mitral Regurgitation Pipeline","og_description":"Peijia Medical Ltd (HKG:\u202f9996) announced completion of the first patient implant in the Early Feasibility Study (EFS) for its GeminiOne transcatheter edge\u2011to\u2011edge repair (TEER) system in the United States. The milestone marks Peijia's entry into the US structural heart market with its next\u2011generation mitral valve repair technology.","og_url":"https:\/\/flcube.com\/?p=62911","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-12T03:50:14+00:00","article_modified_time":"2026-04-12T03:50:15+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1203.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62911#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62911"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System \u2013 Expands Global Mitral Regurgitation Pipeline","datePublished":"2026-04-12T03:50:14+00:00","dateModified":"2026-04-12T03:50:15+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62911"},"wordCount":327,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=62911#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1203.webp","keywords":["Clinical trial approval \/ initiation","CVD","HKG: 9996","Peijia Medical"],"articleSection":["Company","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62911#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62911","url":"https:\/\/flcube.com\/?p=62911","name":"Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System \u2013 Expands Global Mitral Regurgitation Pipeline - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=62911#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=62911#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1203.webp","datePublished":"2026-04-12T03:50:14+00:00","dateModified":"2026-04-12T03:50:15+00:00","description":"Peijia Medical Ltd (HKG:\u202f9996) announced completion of the first patient implant in the Early Feasibility Study (EFS) for its GeminiOne transcatheter edge\u2011to\u2011edge repair (TEER) system in the United States. The milestone marks Peijia's entry into the US structural heart market with its next\u2011generation mitral valve repair technology.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62911#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62911"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=62911#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1203.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1203.webp","width":1080,"height":608,"caption":"Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System \u2013 Expands Global Mitral Regurgitation Pipeline"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62911#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Peijia Medical Doses First Patient in US Early Feasibility Study for GeminiOne TEER System \u2013 Expands Global Mitral Regurgitation Pipeline"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/04\/1203.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62911","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62911"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62911\/revisions"}],"predecessor-version":[{"id":62914,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62911\/revisions\/62914"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/62913"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62911"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62911"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62911"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}